Lexeo Therapeutics, Inc. Common Stock

NasdaqGM LXEO

Lexeo Therapeutics, Inc. Common Stock Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -67.36 M

Lexeo Therapeutics, Inc. Common Stock Free Cash Flow is USD -67.36 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -8.05% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.
  • Lexeo Therapeutics, Inc. Common Stock Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -62.34 M.
Key data
Date Free Cash Flow Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities
Market news
NasdaqGM: LXEO

Lexeo Therapeutics, Inc. Common Stock

CEO Mr. R. Nolan Townsend
IPO Date Nov. 3, 2023
Location United States
Headquarters 345 Park Avenue South
Employees 69
Sector Health Care
Industries
Biotechnology Clinical Trials Pharmaceuticals
Description

Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

StockViz Staff

January 15, 2025

Any question? Send us an email